Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
1.810
+0.080 (4.62%)
At close: Jun 26, 2026, 4:00 PM EDT
1.830
+0.020 (1.10%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Company Description
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages.
Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science S.p.A.
| Country | Italy |
| Founded | 2014 |
| IPO Date | Dec 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Pierluigi Paracchi |
Contact Details
Address: Via Olgettina No. 58 Milan, Michigan 20132 Italy | |
| Website | genenta.com |
Stock Details
| Ticker Symbol | GNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.50 |
| CIK Code | 0001838716 |
| CUSIP Number | 36870W100 |
| ISIN Number | US36870W1009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pierluigi Paracchi | Co-Founder, Chairman, Chief Executive Officer and GM |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | CO-Founder and Scientific Advisory Board Member |
| Richard B. Slansky | Principal Financial and Accounting Officer |
| Gianfranco De Nigris | Vice President Corporate Development |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer, Head of Development and Director |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development |
| Barbara Regonini | Director of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 6-K | Report of foreign issuer |
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 17, 2026 | 6-K | Report of foreign issuer |
| Jun 16, 2026 | 6-K | Report of foreign issuer |
| May 29, 2026 | 6-K | Report of foreign issuer |
| May 19, 2026 | 6-K | Report of foreign issuer |
| May 5, 2026 | SCHEDULE 13D | Filing |
| Apr 28, 2026 | 6-K | Report of foreign issuer |
| Apr 23, 2026 | 6-K | Report of foreign issuer |
| Apr 14, 2026 | 6-K | Report of foreign issuer |